Related references
Note: Only part of the references are listed.MK2 is a therapeutic target for high-risk multiple myeloma
Chunyan Gu et al.
HAEMATOLOGICA (2021)
MK2 is a therapeutic target for high-risk multiple myeloma
Chunyan Gu et al.
HAEMATOLOGICA (2021)
Selective inhibition of CDK4/6: A safe and effective strategy for developing anticancer drugs
Kai Yuan et al.
ACTA PHARMACEUTICA SINICA B (2021)
An updated patent review of anticancer Hsp90 inhibitors (2013-present)
Li Li et al.
EXPERT OPINION ON THERAPEUTIC PATENTS (2021)
RFWD2 induces cellular proliferation and selective proteasome inhibitor resistance by mediating P27 ubiquitination in multiple myeloma
Chunyan Gu et al.
LEUKEMIA (2021)
The Development of Hsp90β-Selective Inhibitors to Overcome Detriments Associated with pan-Hsp90 Inhibition
Sanket J. Mishra et al.
JOURNAL OF MEDICINAL CHEMISTRY (2021)
Selective Inhibition of the Hsp90α Isoform
Sanket J. Mishra et al.
ANGEWANDTE CHEMIE-INTERNATIONAL EDITION (2021)
The IMiD target CRBN determines HSP90 activity toward transmembrane proteins essential in multiple myeloma
M. Heider et al.
MOLECULAR CELL (2021)
Diagnosis, grading and management of toxicities from immunotherapies in children, adolescents and young adults with cancer
Dristhi Ragoonanan et al.
NATURE REVIEWS CLINICAL ONCOLOGY (2021)
Chimeric antigen receptor T-cell therapy in multiple myeloma: a systematic review and meta-analysis of 950 patients
Ghulam Rehman Mohyuddin et al.
BLOOD ADVANCES (2021)
CHEK1 and circCHEK1_246aa evoke chromosomal instability and induce bone lesion formation in multiple myeloma
Chunyan Gu et al.
MOLECULAR CANCER (2021)
The disruption of protein-protein interactions with co-chaperones and client substrates as a strategy towards Hsp90 inhibition
Michael A. Serwetnyk et al.
ACTA PHARMACEUTICA SINICA B (2021)
AHA1 upregulates IDH1 and metabolic activity to promote growth and metastasis and predicts prognosis in osteosarcoma
Diwei Zheng et al.
SIGNAL TRANSDUCTION AND TARGETED THERAPY (2021)
Enhancing global access to cancer medicines
Javier Cortes et al.
CA-A CANCER JOURNAL FOR CLINICIANS (2020)
Cancer statistics, 2020
Rebecca L. Siegel et al.
CA-A CANCER JOURNAL FOR CLINICIANS (2020)
Recent update on discovery and development of Hsp90 inhibitors as senolytic agents
Sayan Dutta Gupta et al.
INTERNATIONAL JOURNAL OF BIOLOGICAL MACROMOLECULES (2020)
Trifolirhizin induces autophagy-dependent apoptosis in colon cancer via AMPK/mTOR signaling
Dongdong Sun et al.
SIGNAL TRANSDUCTION AND TARGETED THERAPY (2020)
A review of cardiac glycosides: Structure, toxicokinetics, clinical signs, diagnosis and antineoplastic potential
Ana Flavia M. Botelho et al.
TOXICON (2019)
New therapeutic aspects of steroidal cardiac glycosides: the anticancer properties of Huachansu and its main active constituent Bufalin
Chien-shan Cheng et al.
CANCER CELL INTERNATIONAL (2019)
Targeting cyclin-dependent kinases for the treatment of pulmonary arterial hypertension
Astrid Weiss et al.
NATURE COMMUNICATIONS (2019)
Potent and Preferential Degradation of CDK6 via Proteolysis Targeting Chimera Degraders
Shang Su et al.
JOURNAL OF MEDICINAL CHEMISTRY (2019)
Targeting MK2 Is a Novel Approach to Interfere in Multiple Myeloma
Mengjie Guo et al.
FRONTIERS IN ONCOLOGY (2019)
Cancer statistics, 2019
Rebecca L. Siegel et al.
CA-A CANCER JOURNAL FOR CLINICIANS (2019)
Exosome-Transmitted PSMA3 and PSMA3-AS1 Promote Proteasome Inhibitor Resistance in Multiple Myeloma
Hongxia Xu et al.
CLINICAL CANCER RESEARCH (2019)
Bortezomib before and after high-dose therapy in myeloma: long-term results from the phase III HOVON-65/GMMGHD-4 trial
H. Goldschmidt et al.
LEUKEMIA (2018)
UniProt: the universal protein knowledgebase (vol 45, pg D158, 2017)
Alexandre Renaux
NUCLEIC ACIDS RESEARCH (2018)
H6, a novel hederagenin derivative, reverses multidrug resistance in vitro and in vivo
Yanting Yang et al.
TOXICOLOGY AND APPLIED PHARMACOLOGY (2018)
Upregulation of FOXM1 in a subset of relapsed myeloma results in poor outcome
Chunyan Gu et al.
BLOOD CANCER JOURNAL (2018)
BF211, a derivative of bufalin, enhances the cytocidal effects in multiple myeloma cells by inhibiting the IL-6/JAK2/STAT3 pathway
Xiao-yu Wu et al.
INTERNATIONAL IMMUNOPHARMACOLOGY (2018)
Proteomic interrogation of HSP90 and insights for medical research
Lorenz Weidenauer et al.
EXPERT REVIEW OF PROTEOMICS (2017)
Hsp90 activator Aha1 drives production of pathological tau aggregates
Lindsey B. Shelton et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2017)
Differential Regulation of G1 CDK Complexes by the Hsp90-Cdc37 Chaperone System
Stephen T. Hallett et al.
CELL REPORTS (2017)
Multiple myeloma
Shaji K. Kumar et al.
NATURE REVIEWS DISEASE PRIMERS (2017)
Tumor suppressor Tsc1 is a new Hsp90 co-chaperone that facilitates folding of kinase and non-kinase clients
Mark R. Woodford et al.
EMBO JOURNAL (2017)
FOXM1 is a therapeutic target for high-risk multiple myeloma
C. Gu et al.
LEUKEMIA (2016)
STRUCTURAL BIOLOGY Atomic structure of Hsp90-Cdc37-Cdk4 reveals that Hsp90 traps and stabilizes an unfolded kinase
Kliment A. Verba et al.
SCIENCE (2016)
NEK2 Induces Drug Resistance Mainly through Activation of Efflux Drug Pumps and Is Associated with Poor Prognosis in Myeloma and Other Cancers
Wen Zhou et al.
CANCER CELL (2013)
Traditional Chinese medicine: theoretical background and its use in China
Márk Oravecz et al.
ORVOSI HETILAP (2012)
Pharmacogenomics of bortezomib test-dosing identifies hyperexpression of proteasome genes, especially PSMD4, as novel high-risk feature in myeloma treated with Total Therapy 3
John D. Shaughnessy et al.
BLOOD (2011)
Conformational dynamics of the molecular chaperone Hsp90
Kristin A. Krukenberg et al.
QUARTERLY REVIEWS OF BIOPHYSICS (2011)
Gene expression profiling for molecular classification of multiple myeloma in newly diagnosed patients
Annemiek Broyl et al.
BLOOD (2010)
Identifying and Characterizing Binding Sites and Assessing Druggability
Thomas A. Halgren
JOURNAL OF CHEMICAL INFORMATION AND MODELING (2009)
Near-native structure refinement using in vacuo energy minimization
Christopher M. Summa et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2007)
New method for fast and accurate binding-site identification and analysis
Tom Halgren
CHEMICAL BIOLOGY & DRUG DESIGN (2007)
The molecular classification of multiple myeloma
Fenghuang Zhan et al.
BLOOD (2006)
Glide: A new approach for rapid, accurate docking and scoring. 1. Method and assessment of docking accuracy
RA Friesner et al.
JOURNAL OF MEDICINAL CHEMISTRY (2004)
Structural basis for recruitment of the ATPase activator Aha1 to the Hsp90 chaperone machinery (vol 23, pg 511, 2004)
P Meyer et al.
EMBO JOURNAL (2004)
Heat shock protein 90 as a molecular target for cancer therapeutics
JS Isaacs et al.
CANCER CELL (2003)
Share Paper
